Laroprovstat + rosuvastatin
Laroprovstat + rosuvastatin has been studied in 1 paper since 2025: none in people yet; 1 in the past year. No study of it in people or animals has been published yet. The newest paper, Nov 3, 2025: “Model-Based Evaluation of LDL-C Lowering for Laroprovstat (AZD0780), An Oral Small Molecule PCSK9 Inhibitor, and Rosuvastatin”.
- In silico1
What did studies of Laroprovstat + rosuvastatin find?
1Studies of Laroprovstat + rosuvastatin measured 1 outcome; the most studied are LDL-C (1 study).
LDL-C
downin silico1
1 study
LDL-C
downin silico1
Laroprovstat + rosuvastatin decreases LDL-C in silico (-76% (95% CI: -86% to -62%)).
“combination of rosuvastatin 20 mg and laroprovstat 30 mg resulted in a predicted mean LDL-C reduction of –76% (95% CI: –86% to –62%) at Week 12”
In silicorosuvastatin 20 mg and laroprovstat 30 mg12 weeks
AHA Scientific Sessions 2025 abstract
Latest
2 papers in 12 monthsAHA Scientific Sessions 2025 Abstract
Laroprovstat (AZD0780) an oral, small molecule PCSK9 inhibitor demonstrates improvements in the lipid profile in participants with hypercholesterolemia: Results from a Phase 1 study
Randomized trial in peopleStatins
AHA Scientific Sessions 2025 Abstract
Model-Based Evaluation of LDL-C Lowering for Laroprovstat (AZD0780), An Oral Small Molecule PCSK9 Inhibitor, and Rosuvastatin
Computational studyStatins